Mizuho analyst, Eric Criscuolo, cut his price target on Myriad Genetics (NASDAQ: MYGN) to $34 from $42 and reduced the projected PE multiple to 20x from 22x. No change to Neutral rating.

Myriad beat consensus top line estimates by $6mm and EPS by $0.03. Hereditary Cancer and Vectra DA were essentially in line with estimates, while Pharma Services and Prolaris were ahead. The key question is the reimbursement gains for Vectra DA and Prolaris.

For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.

Shares of Myriad Genetics closed at $36.19 yesterday.